TOPLINE: Inotuzumab ozogamicin (IO), an anti‐CD22 antibody conjugated with calicheamicin, was well tolerated and demonstrated an overall response rate of 74% in adult patients with relapsed/refractory B-cell acute lymphoblastic leukaemia (B-ALL) in a real-world study. METHODOLOGY: Researchers conducted a multicentre retrospective cohort study involving 73 adult patients (median age at IO initiation...
256 W Beech St P.O. Box 32 Harrison, Michigan, USA 48625
(989) 424-9929
austin@clippershipsandcaravans.com
Copyright © 2023 roenews2. All Rights Reserved
